Azenta (AZTA) Stock Price, News & Analysis

Company Overview

Azenta, Inc. (NASDAQ: AZTA) is a life sciences technology company specializing in advanced sample management, genomic research services and laboratory automation solutions. The company provides critical infrastructure for biopharmaceutical, academic and government research institutions, enabling efficient storage, retrieval and analysis of biological samples. Its offerings span from automated cryogenic storage systems and consumables to high-throughput sequencing, gene synthesis and cell line development services.

Azenta traces its roots to the life sciences division of a legacy automation firm before spinning off as an independent, publicly traded entity in late 2021. The rebranding to Azenta followed several strategic acquisitions, including a leading genomics services provider, which expanded its capabilities in next-generation sequencing and molecular assay development. This evolution has positioned Azenta as a one-stop partner for sample lifecycle management and genomic workflow solutions.

The company’s product portfolio encompasses temperature-controlled sample storage and transportation platforms, automated robotic workstations for liquid handling and assay setup, and a suite of consumables designed for ultra-low temperature and ambient conditions. In addition, Azenta’s genomics services division offers custom DNA synthesis, RNA sequencing, single-cell analysis and bioinformatics support, catering to drug discovery, diagnostic development and personalized medicine projects.

Operating across North America, Europe and the Asia-Pacific region, Azenta serves a diverse customer base that includes pharmaceutical giants, biotech startups and research universities. The business is guided by a seasoned executive leadership team with deep expertise in life sciences, automation engineering and supply chain management. Under the stewardship of President and CEO Bob Chorush, Azenta continues to invest in innovation and global infrastructure to support the accelerating pace of scientific discovery.

Key Stats

• Today's Range: $32.12 to $33.30
• 50-Day Range: $25.30 to $34.15
• 52-Week Range: $23.91 to $63.58
• Volume: 506,645 shs
• Average Volume: 787,588 shs
• Market Capitalization: $1.48 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Moderate Buy

Azenta Stock Analysis - MarketRank™

Azenta scored higher than 64% of companies evaluated by MarketBeat, and ranked 373rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Azenta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Azenta has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 73.58%

Earnings Growth

Earnings for Azenta are expected to grow by 73.58% in the coming year, from $0.53 to $0.92 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Azenta is -23.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Azenta is -23.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Azenta has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.94% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Azenta has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Azenta does not currently pay a dividend.

Dividend Growth

Azenta does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Azenta will have a dividend payout ratio of 10.87% next year. This indicates that Azenta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.94% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Azenta has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.77

News Sentiment

Azenta has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Azenta this week, compared to 5 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azenta insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.62% of the stock of Azenta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.08% of the stock of Azenta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZTA Stock Analysis - Frequently Asked Questions

How have AZTA shares performed this year?

Azenta's stock was trading at $50.00 on January 1st, 2025. Since then, AZTA stock has decreased by 35.5% and is now trading at $32.23.

How were Azenta's earnings last quarter?

Azenta, Inc. (NASDAQ:AZTA) issued its quarterly earnings data on Wednesday, May, 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The firm's revenue for the quarter was up 5.1% on a year-over-year basis.
Read the conference call transcript.

Who are Azenta's major shareholders?

Azenta's top institutional investors include Exchange Traded Concepts LLC (0.91%), Counterpoint Mutual Funds LLC (0.02%), Kera Capital Partners Inc. (0.02%) and NorthCrest Asset Manangement LLC (0.02%). Insiders that own company stock include John Marotta, David C Gray, Matthew Mcmanus, Herman Cueto, Olga Pirogova, William L Cornog and Violetta Hughes.
View institutional ownership trends.

How do I buy shares of Azenta?

Shares of AZTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Azenta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azenta investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:AZTA
• CIK: 933974
• Web: www.brooks.com
• Phone: (978) 262-2400
• Fax: 978-262-2500
• Employees: 3,300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Azenta: $45.00
• High Price Target: $60.00
• Low Price Target: $35.00
• Potential Upside/Downside: +39.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 60.68
• P/E Growth: N/A
• Net Income: -$164.17 million
• Net Margins: -10.31%
• Pretax Margin: -25.70%
• Return on Equity: 1.30%
• Return on Assets: 1.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.22
• Quick Ratio: 2.84

Sales & Book Value

• Annual Sales: $669.17 million
• Price / Sales: 2.20
• Cash Flow: $4.37 per share
• Price / Cash Flow: 7.36
• Book Value: $36.16 per share
• Price / Book: 0.89

Miscellaneous

• Outstanding Shares: 45,780,000
• Free Float: 40,918,000
• Market Cap: $1.47 billion
• Optionable: Optionable
• Beta: 1.64